跳至主要内容
临床试验/CTRI/2023/10/058202
CTRI/2023/10/058202招募中Unknown

Evaluating the Use of Patient-Reported Outcome Measures for Improving the Inter-RaterReliability of Common Terminology Criteria for Adverse Event Ratings - nil

European Organisation for Research and Treatment of Cancer0 个研究点目标入组 0 人开始时间: 待定最近更新:

试验速览

阶段
Unknown
状态
招募中
发起方

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

入选标准

  • 1.The study population will be adult cancer patients fulfilling the following inclusion criteria: patients
  • aged above 18.
  • 2.Any cancer diagnosis (no more than 20% per diagnostic group) current treatment with chemotherapy or immunotherapy inpatient or day clinic setting
  • 3.Scoring 3 or above on an initial screening question (On a scale of 0 to 10, to what degree did you experience physical or emotional symptoms/problems during the last week? ?).
  • 4.No severe cognitive impairments written informed consent.
  • Inclusion criteria for physicians performing CTCAE ratings will be at least one year of professional experience in oncology. Chemotherapy has been selected because the EORTC QLQ-C30 covers common AEs associated with this treatment. Immunotherapy has been added for being an increasingly important treatment option.

排除标准

  • There are no exclusion criteria for this study. All types of cancer patients will be enrolled on the study.

研究者

发起方
European Organisation for Research and Treatment of Cancer

相似试验

Evaluating the Use of PRO Measures for Improving the... | 临床试验